Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Recurrent mutations at R140 and R172 in isocitrate dehydrogenase 2 (IDH2) occur in many cancers, including ∼12% of acute myeloid leukemia (AML). In preclinical models these mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG) and induce hematopoietic differentiation b...

Full description

Saved in:
Bibliographic Details
Published in:Blood
Main Authors: Amatangelo, Michael D., Quek, Lynn, Shih, Alan, Stein, Eytan M., Roshal, Mikhail, David, Muriel D., Marteyn, Benoit, Farnoud, Noushin Rahnamay, de Botton, Stephane, Bernard, Olivier A., Wu, Bin, Yen, Katharine E., Tallman, Martin S., Papaemmanuil, Elli, Penard-Lacronique, Virginie, Thakurta, Anjan, Vyas, Paresh, Levine, Ross L.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2017
Subjects:
Clinical Trials and Observations
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5553578/
https://ncbi.nlm.nih.gov/pubmed/28588019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-779447
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items